{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-172782","form_type":"8-K","ticker":null,"cik":"0001651311","company_name":"Merus N.V.","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.967453+00:00","generated_at":"2026-06-01T00:03:59.221560+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Merus appoints Fabian Zohren as CMO with $503K salary; CBO Liu and former CMO Joe depart","bullets":["Fabian Zohren named Chief Medical Officer effective July 1, 2024, succeeding Andrew Joe.","Zohren's base salary $503,000, target bonus 40%, option for 183,943 shares vesting over 4 years.","Hui Liu (CBO) and Andrew Joe (outgoing CMO) separated same date; severance per agreements.","Liu receives accelerated vesting of 3,000 RSUs and $17,500 lump sum; option extended to Dec 31, 2024.","Joe enters 3-month consulting agreement at $41,000/month; option extended to 3 months post-consulting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-172782","json":"https://secwatch.observer/filing/0001193125-24-172782.json","markdown":"https://secwatch.observer/filing/0001193125-24-172782.md","text":"https://secwatch.observer/filing/0001193125-24-172782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524172782/0001193125-24-172782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524172782/d862441d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:03:59.221560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2569fcf1c2","claim":"Fabian Zohren was appointed as Chief Medical Officer at Merus N.V..","evidence_excerpt":"On June 30, 2024, the Board of Directors (the “Board”) of Merus N.V. (the “Company”) appointed Fabian Zohren, M.D., Ph.D. to serve as the Company’s Chief Medical Officer, effective as of July 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524172782/0001193125-24-172782-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"b251ff70ee","claim":"Andrew Joe departed as Chief Medical Officer at Merus N.V..","evidence_excerpt":"succeeding Andrew Joe, M.D. in such role","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651311/000119312524172782/0001193125-24-172782-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}